BIOCON slid -2.4% on volume spike 3.1x
Biocon Ltd. ended the 7 August session at ₹426.35, down 2.35% from the previous close of ₹436.60. It gapped down 1.51% at the open, and the day's high of ₹436.20 never reached the previous close. The low was ₹425.30, and while one session flag reads "At day's low", the close of ₹426.35 sits just above it — read that flag as an intraday stamp, not the finish. It closed 0.57% below VWAP, the day's volume-weighted average price. The Nifty was 0.27% lower, so this was the bigger fall.
On derivatives there is nothing to report, and that is a data gap rather than a finding. The pack's F&O positioning field is absent altogether — not an empty record showing no activity, but no record at all. Nothing can be said about open interest or futures and options positioning.
The volume evidence contradicts itself, which is worth naming. The session flags include "Volume spike 3.1x", while the technicals block puts relative volume at 0.76, meaning turnover below the stock's own recent norm. Both cannot be right, and nothing in the pack decides between them.
The institutional record is stale: every entry in the 30-day block-and-bulk-deal list is stamped 14 July, with nothing dated to this session. It shows Mylan Inc. selling ₹1,839.34 crore, ICICI Prudential Mutual Fund buying ₹737.5 crore, and HDFC Mutual Fund and Kotak Mahindra Mutual Fund each at ₹233.16 crore on the buy side; two rows appear twice, so those figures should not be summed. The insider list, by contrast, is a genuine empty record: no filings in 60 days. The institutional-streak field, like F&O, is missing.
The medium-term picture barely moved. RSI stood at 49.6, squarely mid-range, and the price stayed above both its 50-day and 200-day moving averages, with no golden or death cross, no Darvas breakout and the trend template unmet. The stock was 4.65% below its 52-week high and 28.81% above its 52-week low, up 0.15% over one week and up 5.6% over one month — a 2.35% day did not overturn that drift.
Only one news item is fresh: GuruFocus.com published highlights from Biocon Ltd.'s Q1 2027 earnings call, its headline flagging biosimilars up 16% alongside a net-profit figure the headline cuts off. The rest is the Mylan cluster from 23 to 25 days ago: Reuters reported Mylan planning to sell up to $363 million of its stake, hdfcsky.com reported the exit via a ₹3,679 crore block deal, and Moneycontrol.com and CNBC TV18 reported the stock rising on it. NDTV Profit reported Bernstein keeping an 'Underperform' rating; a Religare Broking note carried by Investment Guru India ran the other way. All concern Biocon Ltd. itself, not Biocon Biologics or Syngene, which are separate entities.
The data therefore shows no single obvious catalyst. Nothing in the pack is dated to the session: the deal news and deal record are three weeks old, the derivatives footprint is missing, and the volume signal disagrees with itself. What is visible is a gap-down that held and a close near the low.
The numbers
- Last price ₹426.35, -2.35% on the day
- Day range ₹425.30 – ₹436.20
- Opening gap -1.51%
- NIFTY moved -0.27% the same session
Signals that fired
- Volume spike 3.1x
- At day's low
- Gap-and-hold -1.5%
- Below VWAP -0.57%
Institutional activity
| Date | Side | Counterparty | Type | ₹ Cr |
|---|---|---|---|---|
| 2026-07-14 | SELL | MYLAN INC. | Other | 1,839.3 |
| 2026-07-14 | SELL | MYLAN INC. | Other | 1,839.3 |
| 2026-07-14 | BUY | ICICI PRUDENTIAL MUTUAL FUND | MF | 737.5 |
| 2026-07-14 | BUY | ICICI PRUDENTIAL MUTUAL FUND | MF | 737.5 |
| 2026-07-14 | BUY | HDFC MUTUAL FUND | MF | 233.2 |
| 2026-07-14 | BUY | KOTAK MAHINDRA MUTUAL FUND | MF | 233.2 |
Technical context
Volume ran at 0.8× its 20-day average; rsi(14) sits at 50; price is 4.7% from the 52-week high; trading above the 50-dma and 200-dma.
Recent headlines
- Biocon Ltd (BOM:532523) (Q1 2027) Earnings Call Highlights: Biosimilars Surge 16% as Net Profit ... — GuruFocus.com (1d ago)
- Bonus + Stock Splits + Dividends + Buybacks From June 29-July 3: Bajaj, M&M, Biocon, TechM; 46 Stocks In Focus — Goodreturns (1d ago)
- Stock of the day - Biocon Ltd Target Rs. 464 - Religare Broking Ltd — Investment Guru India (14d ago)
- Biocon Shares in Focus as Mylan Exits via ₹3,679 Crore Block Deal — hdfcsky.com (23d ago)
- Biocon-Mylan Share Sale: Bernstein Retains 'Underperform', Flags Three Key Risks Ahead — Check Target Price, Potential Upside And More — NDTV Profit (23d ago)
- Biocon stock jumps 6%, top midcap gainer today as Rs 3,680 crore block deal clears Mylan overhang — Moneycontrol.com (24d ago)
- Biocon shares jump 7% after equity worth ₹3,680 crore changes hands in block window deal — CNBC TV18 (24d ago)
- Mylan to sell up to $363 million stake in India's Biocon, term sheet shows — Reuters (25d ago)
Sources
- Biocon Ltd (BOM:532523) (Q1 2027) Earnings Call Highlights: Biosimilars Surge 16% as Net Profit ... — GuruFocus.com
- Bonus + Stock Splits + Dividends + Buybacks From June 29-July 3: Bajaj, M&M, Biocon, TechM; 46 Stocks In Focus — Goodreturns
- Stock of the day - Biocon Ltd Target Rs. 464 - Religare Broking Ltd — Investment Guru India
- Biocon Shares in Focus as Mylan Exits via ₹3,679 Crore Block Deal — hdfcsky.com
- Biocon-Mylan Share Sale: Bernstein Retains 'Underperform', Flags Three Key Risks Ahead — Check Target Price, Potential Upside And More — NDTV Profit
- Biocon stock jumps 6%, top midcap gainer today as Rs 3,680 crore block deal clears Mylan overhang — Moneycontrol.com
- Biocon shares jump 7% after equity worth ₹3,680 crore changes hands in block window deal — CNBC TV18
- Mylan to sell up to $363 million stake in India's Biocon, term sheet shows — Reuters
Keep digging
- BIOCON — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.